Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

New coagulation factor XIa inhibitors synthesized at Janssen Pharmaceutica

Feb. 18, 2022

HMB-001 bispecific antibody shows promise for treating Glanzmann thrombasthenia

Feb. 15, 2022

Janssen Pharmaceutica presents new factor XIa inhibitors

Feb. 14, 2022

Heterozygous variants in the CD36 gene linked to bleeding phenotypes

Feb. 8, 2022

A microbiota-macrophage-iron axis regulates hematopoietic stem cell fate decisions under stress

Feb. 3, 2022

HMGB1 restricts EPO signaling, contributing to anemia of inflammation

Feb. 2, 2022

MAP3K7 modulation to treat MDS-associated anemia

Jan. 10, 2022

Hematologic

Jan. 1, 2022

Emendo Biotherapeutics develops CRISPR-based ex-vivo gene editing strategy for ELANE neutropenia

Dec. 29, 2021

Factor V/Va-targeting MAb GB-5 promotes thrombus formation in vivo for treating bleeding disorders

Dec. 17, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...